Catalog No.S1840 Synonyms: nsc79037
Molecular Weight(MW): 233.7
Lomustine inhibits cancer cells by damaging the DNA and stops cells from dividing.
Purity & Quality Control
Choose Selective DNA/RNA Synthesis Inhibitors
|Description||Lomustine inhibits cancer cells by damaging the DNA and stops cells from dividing.|
|Features||A more specific and potent anti-medulloblastoma agent compared to Vincristine.|
Lomustine inhibits the growth of ZR-75-1 and U373 with IC50 of 12 μM and 15 μM, respectively. Lomustine reduces the level of expression of the DNA repair protein O6-alkylguanine-DNA alkyltransferase.  Lomustine (420 μM) triggers apoptosis through the mitochondrial pathway via decrease in the level of the anti-apoptosis proteins Bcl-2 and Bcl-xl, respectively, in both medulloblastoma and normal human epithelial and fibroblast cells. Lomustine induces cell cycle delay in G2/M phase in medulloblastoma cells and up-regulates p21 protein level in a p53-independent manner in HFSN1 cells. 
|In vivo||Lomustine can cause delayed, cumulative dose-related, chronic hepatotoxicity that is irreversible and can be fatal.  Lomustine could result in infrequent severe hematological toxicity in cats with spontaneously arising tumors, and the incidence of either grade III or IV neutropenia and thrombocytopenia is 4.1% and 1.0%, respectively. Lomustine trends toward a greater likelihood for progressive neutropenia and statistically significant higher response rates in cats with spontaneously arising tumors. |
-  Baer JC, et al. Br J Cancer, 1993, 67(6), 1299-12302.
-  Shinwari Z, et al. J Neurooncol, 2008, 87(2), 123-132.
-  Rassnick KM, et al. J Vet Intern Med, 1999, 13(6), 601-605.
|In vitro||DMSO||46 mg/mL (196.83 mM)|
|In vivo||Add solvents to the product individually and in order:
30% propylene glycol, 5% Tween 80, 65% D5W, pH 4
For best results, use promptly after mixing.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03022578||Not yet recruiting||Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System|Glioblastoma|Anaplastic Astrocytoma||M.D. Anderson Cancer Center|Monteris Medical||May 2017||Phase 2|
|NCT02986178||Not yet recruiting||Malignant Glioma||Darell D. Bigner, MD, PhD|Duke University||March 2017||Phase 2|
|NCT03025893||Not yet recruiting||Glioblastoma Multiforme|Glioblastoma, Adult|Glioblastoma|Recurrent Brain Tumor|GBM||VU University Medical Center||March 2017||Phase 2|Phase 3|
|NCT02724579||Not yet recruiting||Untreated Childhood Medulloblastoma||Childrens Oncology Group|National Cancer Institute (NCI)||October 2016||Phase 2|
|NCT01775475||Recruiting||AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Diffuse Small Cleaved Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Lymphoblastic Lymphoma|AIDS-related Peripheral/Systemic Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma|Stage III AIDS-related Lymphoma|Stage IV AIDS-related Lymphoma||AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation||September 2016||Phase 2|
|NCT02843230||Not yet recruiting||Glioblastoma||Massachusetts General Hospital||August 2016||--|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.